Dr Anne-Louise Latif

  • Honorary Clinical Senior Lecturer (School of Medicine, Dentistry & Nursing)
  • Affiliate (Institute of Cancer Sciences)

email: Anne-Louise.Latif@glasgow.ac.uk

Institute of Cancer Sciences, Garscube Estate, Beatson Institute

Publications

List by: Type | Date

Jump to: 2021 | 2020 | 2016 | 2015 | 2013
Number of items: 6.

2021

Horne, G. A. , Laird, J., Latif, A.-L., Irvine, D., Wilson, M. and Douglas, K. (2021) The implications of CAR-T cell therapy on apheresis services: a Scottish perspective. Journal of Clinical Apheresis, 36(3), pp. 513-515. (doi: 10.1002/jca.21871) (PMID:33378123)

Latif, A.-L. et al. (2021) BRD4-mediated repression of p53 is a target for combination therapy in AML. Nature Communications, 12(1), 241. (doi: 10.1038/s41467-020-20378-8) (PMID:33431824) (PMCID:PMC7801601)

2020

Horne, G. et al. (2020) A randomised phase II trial of hydroxychloroquine and imatinib versus imatinib alone for patients with chronic myeloid leukaemia in major cytogenetic response with residual disease. Leukemia, 34(7), pp. 1775-1786. (doi: 10.1038/s41375-019-0700-9) (PMID:31925317) (PMCID:PMC7224085)

2016

Latif, A.-L. and Holyoake, T. (2016) Lifting the differentiation embargo. Cell, 167(1), pp. 45-46. (doi: 10.1016/j.cell.2016.08.051) (PMID:27662083)

2015

Latif, A.-L., Cole, J. J., Monteiro Campos, J., Clark, W., McGarry, L., Brock, C., Newcombe, A., Keeshan, K. , Copland, M. and Adams, P. D. (2015) Dual inhibition of MDM2 and BET cooperate to eradicate acute myeloid leukemia. Blood, 126(23), p. 674. (doi: 10.1182/blood.V126.23.674.674)

2013

Sinclair, A., Latif, A.L. and Holyoake, T.L. (2013) Targeting survival pathways in chronic myeloid leukaemia stem cells. British Journal of Pharmacology, 169(8), pp. 1693-1707. (doi: 10.1111/bph.12183)

This list was generated on Thu Sep 23 01:43:31 2021 BST.
Jump to: Articles
Number of items: 6.

Articles

Horne, G. A. , Laird, J., Latif, A.-L., Irvine, D., Wilson, M. and Douglas, K. (2021) The implications of CAR-T cell therapy on apheresis services: a Scottish perspective. Journal of Clinical Apheresis, 36(3), pp. 513-515. (doi: 10.1002/jca.21871) (PMID:33378123)

Latif, A.-L. et al. (2021) BRD4-mediated repression of p53 is a target for combination therapy in AML. Nature Communications, 12(1), 241. (doi: 10.1038/s41467-020-20378-8) (PMID:33431824) (PMCID:PMC7801601)

Horne, G. et al. (2020) A randomised phase II trial of hydroxychloroquine and imatinib versus imatinib alone for patients with chronic myeloid leukaemia in major cytogenetic response with residual disease. Leukemia, 34(7), pp. 1775-1786. (doi: 10.1038/s41375-019-0700-9) (PMID:31925317) (PMCID:PMC7224085)

Latif, A.-L. and Holyoake, T. (2016) Lifting the differentiation embargo. Cell, 167(1), pp. 45-46. (doi: 10.1016/j.cell.2016.08.051) (PMID:27662083)

Latif, A.-L., Cole, J. J., Monteiro Campos, J., Clark, W., McGarry, L., Brock, C., Newcombe, A., Keeshan, K. , Copland, M. and Adams, P. D. (2015) Dual inhibition of MDM2 and BET cooperate to eradicate acute myeloid leukemia. Blood, 126(23), p. 674. (doi: 10.1182/blood.V126.23.674.674)

Sinclair, A., Latif, A.L. and Holyoake, T.L. (2013) Targeting survival pathways in chronic myeloid leukaemia stem cells. British Journal of Pharmacology, 169(8), pp. 1693-1707. (doi: 10.1111/bph.12183)

This list was generated on Thu Sep 23 01:43:31 2021 BST.